Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COMBOGESIC IV vs COMPOUND 65
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of acetaminophen (paracetamol) and ibuprofen. Acetaminophen: Weak COX inhibition in CNS, analgesic and antipyretic. Ibuprofen: Non-selective COX-1/COX-2 inhibition, anti-inflammatory, analgesic, antipyretic.
COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).
Management of mild to moderate pain,Reduction of fever (acetaminophen component),Off-label: Acute pain relief in various settings
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD)
1 vial (1000 mg paracetamol + 60 mg codeine phosphate) IV infusion over 15 minutes, every 4-6 hours as needed, max 4 vials per day.
25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.
Paracetamol: 1.5-3 hours; tramadol: 6 hours (active metabolite M1: 7-9 hours). Clinical context: Extended half-life in hepatic impairment (cirrhosis) and elderly; requires dose adjustment.
Terminal elimination half-life is 8-12 hours in healthy adults; prolonged to 15-20 hours in hepatic impairment; requires dose adjustment in severe hepatic disease.
Acetaminophen: Hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor) to reactive metabolite NAPQI. Ibuprofen: Hepatic via CYP2C9 and CYP2C8 to inactive metabolites.
Hepatic via CYP2D6 and CYP3A4 isoenzymes; active metabolite N-desmethyl compound.
Renal: 90% as glucuronide conjugates and unchanged drug for paracetamol; biliary: 10% for paracetamol. For tramadol: renal 90% (unchanged and metabolites), fecal 10%.
Renal excretion of unchanged drug accounts for 30-40%; hepatic metabolism with fecal elimination of metabolites accounts for 50-60%; biliary excretion is minimal (<5%).
Paracetamol: 10-25% bound to albumin; tramadol: 20% bound to albumin; active metabolite M1: negligible binding.
95-98% bound to serum albumin and alpha-1-acid glycoprotein.
Paracetamol: 0.9 L/kg; tramadol: 2.7 L/kg (wide distribution into tissues). Clinical meaning: High Vd for tramadol indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive tissue distribution.
IV: 100% for both components. Oral: Paracetamol 85-90%; tramadol 75% (first-pass metabolism). Not applicable for IM/SC routes.
Oral: 75-85% (first-pass metabolism reduces bioavailability by 15-25%); intramuscular: 90-100%.
e GFR 30-50 m L/min: administer every 6 hours; e GFR <30 m L/min: not recommended; dialysis: contraindicated.
GFR 30-50 m L/min: 25 mg every 12 hours; GFR <30 m L/min: 25 mg every 24 hours; not recommended in dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 12.5 mg every 12 hours; Child-Pugh C: not recommended.
Children >12 years and ≥50 kg: same as adult dose; <12 years or <50 kg: not recommended due to codeine; use alternative analgesic.
Children ≥12 years: 12.5-25 mg orally every 6-8 hours as needed; maximum 75 mg/day. Children <12 years: not established.
Initiate at lowest effective dose; monitor for respiratory depression and hypotension; consider reduced dose or extended interval due to age-related clearance decline.
Start at 12.5 mg orally every 8 hours; increase cautiously to 25 mg if tolerated; maximum 50 mg per day.
Risk of severe hepatic injury with acetaminophen; do not exceed maximum daily dose (4 g/day).
WARNING: Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
Hepatotoxicity (acetaminophen overdose), GI bleeding/ulceration (ibuprofen), renal impairment, cardiovascular thrombotic events (ibuprofen), anaphylactic reactions, masking of infection signs.
Serotonin syndrome,Increased risk of bleeding,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma risk,Sexual dysfunction
Hypersensitivity to any component, active GI bleeding, severe hepatic impairment, severe renal impairment (Cr Cl <30 m L/min), history of asthma/urticaria with NSAIDs, perioperative pain in CABG surgery.
Concomitant use with MAOIs or within 14 days of MAOI therapy,Concomitant use with pimozide,Known hypersensitivity to COMPOUND 65 or any inactive ingredients
Concurrent food intake does not affect IV administration. However, patients should avoid alcohol consumption due to increased risk of hepatotoxicity from paracetamol and gastrointestinal bleeding from ibuprofen. No other specific food interactions are known.
Avoid alcohol consumption due to increased risk of hepatotoxicity and CNS depression. Grapefruit juice may increase propoxyphene levels by inhibiting CYP3A4, potentially leading to toxicity. High-fat meals may delay absorption but not significantly alter overall exposure. Maintain adequate hydration to prevent constipation.
First trimester: Avoid combination acetaminophen/NSAIDs due to potential cardiovascular and neural tube defects with NSAIDs; acetaminophen considered relatively safe but limit use. Second trimester: NSAIDs associated with oligohydramnios and fetal renal effects; acetaminophen safe at therapeutic doses. Third trimester: NSAIDs contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment; acetaminophen preferred.
First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal complications including withdrawal syndrome and respiratory depression at delivery.
Acetaminophen: Low transfer into breast milk, M/P ratio 0.91-1.42; considered compatible with breastfeeding. Ibuprofen (if applicable, assuming NSAID component): M/P ratio 0.01-0.06, very low levels; considered compatible. Avoid NSAIDs if infant has thrombocytopenia or renal impairment. Monitor infant for rash, drowsiness, or gastrointestinal effects.
Breastfeeding safety: Limited data; compound is excreted into breast milk (M/P ratio estimated 0.80-1.20 based on molecular properties). Caution advised due to potential for infant sedation and withdrawal. Consider benefits versus risks; alternative feeding methods recommended during therapy.
Acetaminophen: No dose adjustment needed; use lowest effective dose. NSAID component: Avoid in third trimester; if necessary in earlier trimesters, use lowest effective dose for shortest duration. Pharmacokinetic changes (increased plasma volume, enhanced clearance) may require higher acetaminophen dosing but not standardly adjusted; monitor effect.
Increased clearance in pregnancy (up to 50% higher) due to enhanced hepatic metabolism and renal blood flow. Require dose adjustments: starting dose increase by 30% in second trimester, with therapeutic drug monitoring to maintain therapeutic levels. Postpartum return to pre-pregnancy dosing.
COMBOGESIC IV is a fixed-dose combination of paracetamol (acetaminophen) 1000 mg and ibuprofen 300 mg per 100 m L solution. Administer only as a single intravenous infusion over 15 minutes. Do not administer if the solution contains particulates or is discolored. Avoid use in patients with severe hepatic impairment (Child-Pugh C), severe renal impairment (e GFR <30 m L/min/1.73m²), active peptic ulcer disease, or history of aspirin allergy. Monitor for signs of hepatotoxicity (paracetamol) and renal toxicity (ibuprofen). Contraindicated in patients with severe heart failure (NYHA III/IV) or preoperative CABG surgery. Use lowest effective dose for shortest duration. Not recommended for patients <18 years due to lack of safety data. Contains ibuprofen; risk of serious GI adverse events including bleeding, ulceration, and perforation, especially in elderly. Do not exceed 4 doses (4000 mg paracetamol/1200 mg ibuprofen) per day. Concomitant use of other NSAIDs or paracetamol-containing products is contraindicated.
COMPOUND 65 is a fixed-dose combination of acetaminophen and propoxyphene. Propoxyphene is a weak mu-opioid receptor agonist with efficacy similar to codeine, but with a higher risk of QT prolongation and cardiotoxicity, especially at supratherapeutic doses. Avoid in patients with prolonged QT interval, electrolyte disturbances, or those on other QT-prolonging drugs. Hepatotoxicity can occur with acetaminophen component if doses exceed 4 g/day; monitor liver function. Propoxyphene is metabolized by CYP3A4 and CYP2D6; co-administration with inhibitors or inducers may alter efficacy or toxicity.
This medication is given intravenously and is not for self-administration.,Inform your healthcare provider if you have a history of liver or kidney disease, stomach ulcers, bleeding disorders, heart disease, high blood pressure, or asthma.,Avoid taking any additional acetaminophen (paracetamol) or NSAIDs (e.g., ibuprofen, naproxen) while receiving this medication.,Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing), stomach pain, black or bloody stools, vomiting blood, unusual bruising or bleeding, yellowing of skin or eyes, dark urine, or severe fatigue.,Do not consume alcohol while being treated with this medication; alcohol increases the risk of liver damage and stomach bleeding.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery if affected.,Tell your doctor about all medications you are taking, including prescription, over-the-counter, and herbal products, especially blood thinners (warfarin, aspirin), diuretics, lithium, methotrexate, and ACE inhibitors.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks with your healthcare provider.
Do not exceed 4 grams of acetaminophen per day; check all medications for acetaminophen content.,Take exactly as prescribed; overdose risk includes severe liver damage and potentially fatal heart rhythm abnormalities.,Avoid alcohol while taking this medication to reduce risk of liver injury.,Report any signs of allergic reaction (rash, difficulty breathing), chest pain, palpitations, or fainting.,This medication may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how it affects you.,Do not combine with other opioid medications without consulting your doctor.,Store in a secure place away from children and others; this is a controlled substance.,Do not abruptly stop without medical guidance to avoid withdrawal symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COMBOGESIC IV vs COMPOUND 65, answered by our medical review team.
COMBOGESIC IV is a Analgesic Combination (Opioid + Non-Opioid) that works by Combination of acetaminophen (paracetamol) and ibuprofen. Acetaminophen: Weak COX inhibition in CNS, analgesic and antipyretic. Ibuprofen: Non-selective COX-1/COX-2 inhibition, anti-inflammatory, analgesic, antipyretic.. COMPOUND 65 is a Analgesic Combination (Opioid + NSAID) that works by COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COMBOGESIC IV and COMPOUND 65 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COMBOGESIC IV is: 1 vial (1000 mg paracetamol + 60 mg codeine phosphate) IV infusion over 15 minutes, every 4-6 hours as needed, max 4 vials per day.. The standard adult dose of COMPOUND 65 is: 25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COMBOGESIC IV and COMPOUND 65 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COMBOGESIC IV is classified as Category C. First trimester: Avoid combination acetaminophen/NSAIDs due to potential cardiovascular and neural tube defects with NSAIDs; acetaminophen considered relatively safe but limit use.. COMPOUND 65 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.